Business & Finance
Flagship’s Afeyan Sees UK Bet Creating Next Moderna
Key Points
Flagship Pioneering founder and CEO Noubar Afeyan says the biotech venture firm hopes its new UK investment can grow to as much as £600 million “relatively soon,” as it establishes its first full-scale company-creation operation outside the US. Speaking on Bloomberg’s “The Pulse With Francine Lacqua”, the Moderna co-founder explains why Flagship chose the UK, how AI could accelerate drug discovery and the creation of new biotech companies, and why governments and industry need agreed...
Flagship Pioneering founder and CEO Noubar Afeyan says the biotech venture firm hopes its new UK investment can grow to as much as £600 million “relatively soon,” as it establishes its first full-scale company-creation operation outside the US. Speaking on Bloomberg’s “The Pulse With Francine Lacqua”, the Moderna co-founder explains why Flagship chose the UK, how AI could accelerate drug discovery and the creation of new biotech companies, and why governments and industry need agreed safeguards for increasingly autonomous AI agents. (Source: Bloomberg)